Limits...
Management of hereditary angioedema: 2010 Canadian approach.

Bowen T, Brosz J, Brosz K, Hebert J, Ritchie B - Allergy Asthma Clin Immunol (2010)

Bottom Line: C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening.Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE.We here present a review of management of HAE in Canada.

View Article: PubMed Central - HTML - PubMed

Affiliation: Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'Angioédème Héréditaire (RCAH), 705 South Tower, 3031 Hospital Dr, NW Calgary, Alberta, Canada. tbowen@pol.net.

ABSTRACT
C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening. Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE. We have formed the Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'Angioédème Héréditaire (RCAH) - http://www.haecanada.com to advance care of patients with this disorder in Canada. We here present a review of management of HAE in Canada.

No MeSH data available.


Related in: MedlinePlus

Treatment of Acute Hereditary Angioedema - HAE - Attacks.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2921103&req=5

Figure 3: Treatment of Acute Hereditary Angioedema - HAE - Attacks.

Mentions: In Canada, blood products are provided without charge to the patient and are funded through an interprovincial-territorial funded government program. There is a central distribution system through Canadian Blood Services for nine of the ten provinces and three Territories or through Hema-Quebec in Quebec so national statistics are available for fractionation blood products. Non-blood products used in HAE are harder to track depending on how the product is distributed. Intravenous C1 inhibitor replacement therapy (C1INHRP, Berinert®, CSL Behring) has been licensed for use in Canada in 2010. Icatibant (Firazyr®, Shire Pharmaceuticals), ecallantide (Kalbitor®, Dyax), and recombinant C1-INH (Rhucin®, Pharming Group NV) have been on clinical trial in Canada. C1INHRP has been licensed in the United States (Cinryze®, ViroPharma Incorporated, licensed for prophylaxis of angioedema events; Berinert®, CSL Behring, licensed for therapy of angioedema events). Ecallantide (Kalbitor®, Dyax) has been licensed in the United States for therapy of angioedema events. Icatibant (Firazyr®, Shire Pharmaceuticals) has been licensed in Europe for therapy of angioedema events. Recombinant C1-INH (Rhucin®, Pharming Group NV) is under investigation for therapy of angioedema events on both sides of the Atlantic. We support the treatment algorithm proposed in the 2010 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema http://www.haecanada.com/files/TreatmentChart100527.pdf;(see Figure 3);[8].


Management of hereditary angioedema: 2010 Canadian approach.

Bowen T, Brosz J, Brosz K, Hebert J, Ritchie B - Allergy Asthma Clin Immunol (2010)

Treatment of Acute Hereditary Angioedema - HAE - Attacks.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2921103&req=5

Figure 3: Treatment of Acute Hereditary Angioedema - HAE - Attacks.
Mentions: In Canada, blood products are provided without charge to the patient and are funded through an interprovincial-territorial funded government program. There is a central distribution system through Canadian Blood Services for nine of the ten provinces and three Territories or through Hema-Quebec in Quebec so national statistics are available for fractionation blood products. Non-blood products used in HAE are harder to track depending on how the product is distributed. Intravenous C1 inhibitor replacement therapy (C1INHRP, Berinert®, CSL Behring) has been licensed for use in Canada in 2010. Icatibant (Firazyr®, Shire Pharmaceuticals), ecallantide (Kalbitor®, Dyax), and recombinant C1-INH (Rhucin®, Pharming Group NV) have been on clinical trial in Canada. C1INHRP has been licensed in the United States (Cinryze®, ViroPharma Incorporated, licensed for prophylaxis of angioedema events; Berinert®, CSL Behring, licensed for therapy of angioedema events). Ecallantide (Kalbitor®, Dyax) has been licensed in the United States for therapy of angioedema events. Icatibant (Firazyr®, Shire Pharmaceuticals) has been licensed in Europe for therapy of angioedema events. Recombinant C1-INH (Rhucin®, Pharming Group NV) is under investigation for therapy of angioedema events on both sides of the Atlantic. We support the treatment algorithm proposed in the 2010 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema http://www.haecanada.com/files/TreatmentChart100527.pdf;(see Figure 3);[8].

Bottom Line: C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening.Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE.We here present a review of management of HAE in Canada.

View Article: PubMed Central - HTML - PubMed

Affiliation: Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'Angioédème Héréditaire (RCAH), 705 South Tower, 3031 Hospital Dr, NW Calgary, Alberta, Canada. tbowen@pol.net.

ABSTRACT
C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening. Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE. We have formed the Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'Angioédème Héréditaire (RCAH) - http://www.haecanada.com to advance care of patients with this disorder in Canada. We here present a review of management of HAE in Canada.

No MeSH data available.


Related in: MedlinePlus